CHRNA7 and schizophrenia: A small, proof-of-concept trial reported that the partial α7nAChR agonist GTS-21 significantly improved neurocognition and P50 inhibition in schizophrenic patients [87], whereas a later phase II trial failed to show any improvement in cognition when patients with schizophrenia were treated with GTS-21 [88].